Literature DB >> 31090188

Association of Hepcidin With Anemia Parameters in Incident Dialysis Patients: Differences Between Dialysis Modalities.

Jeong-Hoon Lim1, Yeong Woo Park2, Sun Hee Lee3, Jun Young Do4, Sung-Ho Kim5, Seungyeup Han6, Hee-Yeon Jung1, Ji-Young Choi1, Jang-Hee Cho1, Chan-Duck Kim1, Sun-Hee Park1, Yong-Lim Kim1.   

Abstract

Hepcidin's relationships with other variables are unclear. We evaluated associations of serum hepcidin with clinical parameters in ESRD patients. Ninety-nine incident dialysis patients, including 57 on peritoneal dialysis (PD) and 42 on HD, were prospectively followed for 6 months. Serum hepcidin levels significantly increased during initial 6 months of dialysis. In the multivariate regression model, independent predictors of serum hepcidin levels in ESRD patients before maintenance dialysis were interleukin-6, ferritin, phosphate, iron, and aspartate transaminase. Six months after initiating dialysis, serum hepcidin levels were independently predicted by ferritin, total iron binding capacity (TIBC), and aspartate transaminase in all patients, whereas by ferritin and TIBC in PD patients, and ferritin, TIBC, and 24-h urine volume in HD patients. Serum hepcidin levels are differentially associated with anemia parameters in PD compared with HD patients. Urine volume was an independent predictor of hepcidin levels in early HD patients.
© 2019 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy.

Entities:  

Keywords:  End-stage renal disease; Hemoglobin; Hepcidin; Iron parameter; Urine volume

Year:  2019        PMID: 31090188     DOI: 10.1111/1744-9987.12837

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  1 in total

1.  Glycochenodeoxycholate Affects Iron Homeostasis via Up-Regulating Hepcidin Expression.

Authors:  Long-Jiao Wang; Guo-Ping Zhao; Xi-Fan Wang; Xiao-Xue Liu; Yi-Xuan Li; Li-Li Qiu; Xiao-Yu Wang; Fa-Zheng Ren
Journal:  Nutrients       Date:  2022-08-02       Impact factor: 6.706

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.